QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
This study aimed to find out if prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can predict cancer progression in patients with low-grade prostate cancer. These patients had been diagnosed with Grade Group (GG) 1 prostate cancer through…
In the context of prostate cancer management, the standard practice of performing bilateral extended pelvic lymph node dissection (PLND) during radical prostatectomy is being questioned with advancements in imaging technology. Magnetic resonance imaging (MRI)-targeted biopsies now provide more accurate staging,…
A recent study led by Burcu F Darst, PhD (University of Washington and Fred Hutchinson Cancer Research Center) investigated the connection between specific genes and the development of aggressive prostate cancer. Gene testing is currently recommended for men who have…
Researchers conducted a meta- analysis of ten genome-wide association studies of more than19,000 cases and 60,000 controls of African ancestry to identify common genetic variants contributing to the risk of prostate cancer in men of African ancestry. They discovered…
Grade group 1 (GG1) prostate cancers, with a Gleason score of 6, are considered low-risk and not likely to lead to death. Because they are generally slow-growing and not aggressive, treatment is often not needed. These cancers rarely spread to…
This study examined the use of PSMA-PET, an advanced imaging technique, and how its use might improve outcomes for patients with recurring prostate cancer. PSMA-PET is more sensitive and specific than older imaging methods like CT scans and bone…
Researchers compared the cardiovascular risks associated with luteinizing hormone-releasing hormone (LHRH) agonists versus gonadotropin-releasing hormone (GnRH) antagonists in prostate cancer patients undergoing androgen deprivation therapy (ADT). Scientists conducted a retrospective analysis using real-world data from more than 45,000 men with…
This study focused on men with prostate cancer who were at high risk for recurrence. Specifically, the researchers were interested in patients whose prostate-specific antigen (PSA) levels were rising quickly. When PSA levels double quickly, there is a higher risk…
This phase II clinical trial (ARTO trial) examined whether adding stereotactic body radiation therapy (SBRT) to a standard treatment of abiraterone acetate and prednisone (AAP) would help improve outcomes for patients with oligometastatic, castrate- resistant prostate cancer (CRPC). Oligometastatic CRPC…
Researchers sought to determine which factors lead to a shorter time to PSA failure, which is a sign of prostate cancer worsening. Their goal was to identify patients who may need more aggressive treatments and to test specified treatments…
"*" indicates required fields
